A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021)

Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey

“…Various chemotherapy regimens of full-dose FP were included: (1) two cycles of cisplatin 70-80 mg/m 2 (day 1) and 5-FU 700-800 mg/m 2 /day administered as continuous intravenous infusion (IV) (days 1-4 or 1-5) [18][19][20], (2) two cycles of cisplatin 40 mg/m 2 (days 1 and 8) and 5-FU 400 mg/m 2 /day as continuous IV (days 1-5 and 8-12) [6,10], and (3) two or three cycles of cisplatin 60 mg/m 2 (day 1) and 5-FU 400 mg/m 2 /day as continuous IV (days 1-4) [9,21]. Low-dose FP included the following regimens: (1) two cycles of cisplatin 7 mg/m 2 (days 1-5 and 8-12) and 5-FU 250 mg/m 2 /day as continuous IV (days 1-14) [5,18,19], and (2) six weekly cycles of cisplatin 3-5 mg/m 2 (days 1-5) and 5-FU 180-250 mg/m 2 as continuous IV (days 1-5 or 1-7) [19,20,22]. The other regimens included: (1) two cycles of cis-diammine-glycolatoplatinum (Nedaplatin) 55-80 mg/m 2 and 5-FU 300-700 mg/m 2 as continuous IV (days 1-5) [23], and (2) daily administration of 5-FU 300 mg/m 2 /day as continuous IV for 6 weeks [7].…”

“…Two cycles of consolidation chemotherapy with cisplatin 70-80 mg/m 2 (day 1) and 5-FU 700-800 mg/m 2 /day (days 1-4 or 1-5) were given after CRT at three institutions [10,18]. No consolidation chemotherapy was given at the remaining six institutions.…”

“…In the present analysis, full-dose FP was used most frequently (42.5%), followed by low-dose FP (36.8%) ( Table 2). During this period, two clinical trials comparing full-dose FP and lowdose FP were performed at several institutions [18,19]. In both trials, protracted low-dose FP with RT provided no advantage over standard short-term full-dose FP with RT for esophageal cancer.…”

A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer

“…However, the survival benefit of these modified regimens remains unclear, despite their ability to alleviate toxicities and improve treatment compliance. Split-or low-dose cisplatin regimens have also been investigated in treatment of other cancers for their efficacy and safety [20][21][22][23][24]. However, in most of these studies, no clinical benefit of a modified dose and schedule of cisplatin has been demonstrated compared with high-to moderatedose cisplatin schedules.…”

Radiation Therapy

“…In a single institute phase II trial of chemoradiotherapy with 5-FU and cisplatin and 60 Gy irradiation for patients with clinical T4 and/or M1 lymph node ESCC, complete response (CR) rate was 33 % and median survival time and 3-year survival rate were 9 months and 23 %, respectively [6]. Another clinical trials of 5-FU and cisplatin and 60 Gy irradiation for patients including clinical T4 showed that CR rate was 15-33 % and 2-year, 3 year survival rates were 27-46 % and 23-30 %, respectively [7,8,[42][43][44]. Other combination regimen using new drugs (paclitaxel, docetaxel, oxaliplatin, S-1, and cetuximab) with concurrent radiotherapy have been evaluated [46][47][48][49].…”